ClinicalTrials.gg
RecruitingNCT06127199Updated Oct 8, 2026

Contraceptive Efficacy Study of Ovaprene

An interventional study of Ovaprene in Contraception, sponsored by Daré Bioscience, Inc.. Recruiting at 27 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Daré Bioscience, Inc. · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
656
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.

02

Conditions studied

  • Contraception

Keywords

  • Device
  • Non-hormonal
03

In context

Lead sponsor

Daré Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sexually active people assigned female at birth, at risk for pregnancy and desiring .
  • General good health, by subject history and per investigator judgement
  • Age 18 through 40 years, inclusive; approximately 66 subjects >35 years old at visit 2 will be the Enrolled-Eligible Population
  • In a relationship with a person assigned male at birth who meets eligibility criteria below.

    --At least 18 years old, not known to be subfertile or infertile

  • Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days, without heave bleeding that lasts longer than 5 days
  • Be willing to stop their current method of contraception (with the exception of condoms) before Visit 2. Participants must experience at least one subsequent menstrual bleed before inserting Ovaprene. Participants using injectable contraception must be at least 9 months post their last dose at screening and have experienced at least 2 subsequent regular menstrual bleeds that were part of cycles of 21-35 days. After stopping their current method of contraception, subjects must either abstain fro vaginal sex or use condoms before inserting their first Ovaprene
  • Not be actively desiring pregnancy for at least 13 months and be willing to accept an unknown risk of pregnancy
  • Expect to engage in at least 4 acts of heterosexual vaginal intercourse per cycle during the study.
  • Be willing to only use Ovaprene as the sole method of contraception over the course of the study
  • Agree not to participate in any other clinical trials during the course of the study
  • Be willing and able to comply with study procedures and to return to the clinic for scheduled follow-up visits
  • Microbiota/innate immunity and colposcopy subsets only:

    • Be willing to avoid vaginal sex and using tampons and other intravaginal products for 48 hours prior to clinic visits; and be willing to comply with subset procedures

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant and/or have a positive urine pregnancy test at screening.
  • Have an allergy to the ingredients in Ovaprene
  • Have a history of toxic shock syndrome
  • Have a history of hereditary hemochromatosis
  • Be breastfeeding an infant
  • Have a history suggestive of infertility, defined as any of the following: known history of ectopic pregnancy or other fertility problem; sterilization/permanent ; endometriosis or hospitalization for pelvic inflammatory disease (PID) unless subject has had a subsequent spontaneous intrauterine pregnancy; or use of medications that could cause subfertility such as gonadotropin-releasing hormone agonists
  • Currently have postcoital bleeding
  • Have to pregnancy (medical condition) or chronic use of medications contraindicated in pregnancy
  • Have a history of uterine prolapse, cystocele, or rectocele that has required surgical intervention or pessary use
  • Positive (HIV) test at screening
  • Have exclusionary results on human papilloma virus (HPV) screening/cytology (subjects>/=21 years old) at screening or require treatment or follow-up for an abnormal Pap smear or HPV test that would be needed during the study.
  • Have had a vaginal or cervical within 1 month or vaginal surgery within the 3 months prior to screening
  • Known current drug or alcohol abuse which, in the opinion of the investigator, could impact study compliance
  • Have previously been included in the Enrolled-Eligible Population
  • Is a direct employee or immediate family member of the Sponsor company, site Investigators or study staff
  • Have taken any drug or used any investigational device within the 30 days prior to screening
  • Have a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results
  • Microbiota/innate immunity subset only:

    --systemic use in the last 2 weeks prior to screening or anticipated use during the study of antibiotics (other than those used to treat urinary tract infection (UTI), candidiasis, or bacterial vaginosis(BV) diagnosed at Visit 1) or antivirals;

  • If male partner has or is suspected to have had an HIV infection or other sexually transmitted infection
  • if male partner has a known sensitivity or allergy to the ingredients in Ovaprene
  • If male partner has previously participated in this study or has taken any investigational drug or used any investigational device within 30 days prior to the female subject's screening
  • If the male partner has a history of any severe acute or chronic medical or psychiatric condition that could increase the risk associated with trial participation or could interfere with the interpretation of trial results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
656 participants (estimated)

Study arms

  • Experimental
    Ovaprene

    Device: Ovaprene

Interventions

  • DeviceOvaprene

    Non-hormonal intravaginal ring

06

What researchers measure

Primary outcomes

  1. Determination of pregnancy rate

    Measurement of number of pregnancies over 13 menstrual cycles (13-cycle Pearl Index)

    Time frame: 12 months

07

Study locations

4 of 27 sites recruiting
  • Precision Trials AZ
    Phoenix, Arizona 85032, United States
    Recruiting
    • Director of Operations · Contactali@precisiontrials.com · 602-931-4507
    • Valerie Sorkin-Wells, MD · Principal investigator
  • MomDoc Women's Health Research
    Scottsdale, Arizona 85251, United States
    Completed

    Not enrolling at this site — choose another above.

  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
    Recruiting
  • Essential Health Access (Berkeley)
    Berkeley, California 94710, United States
    Completed

    Not enrolling at this site — choose another above.

  • Essential Access Health
    Los Angeles, California 90010, United States
    Completed

    Not enrolling at this site — choose another above.

  • Amicis Research Center
    Newhall, California 91321, United States
    Recruiting
  • University of California at Davis
    Sacramento, California 95817, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of California, San Francisco
    San Francisco, California 94143, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Colorado Denver
    Aurora, Colorado 80045, United States
    Completed

    Not enrolling at this site — choose another above.

  • Emory University
    Atlanta, Georgia 30322, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Hawaii
    Honolulu, Hawaii 96826, United States
    Completed

    Not enrolling at this site — choose another above.

  • Praetorian Pharmaceutical Research, LLC
    Marrero, Louisiana 70072, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Johns Hopkins University
    Baltimore, Maryland 21224, United States
    Completed

    Not enrolling at this site — choose another above.

  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Completed

    Not enrolling at this site — choose another above.

  • Washington University
    St Louis, Missouri 63110, United States
    Completed

    Not enrolling at this site — choose another above.

  • Rutgers Medical Center
    Newark, New Jersey 07103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Columbia University
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Einstein College of Medicine
    The Bronx, New York 10461, United States
    Completed

    Not enrolling at this site — choose another above.

  • Carolina Women's Research and Wellness Center
    Durham, North Carolina 27713, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
    Completed

    Not enrolling at this site — choose another above.

  • Case Western
    Cleveland, Ohio 44106, United States
    Completed

    Not enrolling at this site — choose another above.

  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Pennsylvania Penn Obstetric Gynecology Associates
    Philadelphia, Pennsylvania 19104, United States
    Completed

    Not enrolling at this site — choose another above.

  • Magee-Women's Hospital
    Pittsburgh, Pennsylvania 15213, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Utah
    Salt Lake City, Utah 84132, United States
    Completed

    Not enrolling at this site — choose another above.

  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
    Completed

    Not enrolling at this site — choose another above.

  • Seattle Clinical Research Center
    Seattle, Washington 98104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Final decision on what will be shared has not yet been determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Sep 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now completed, 1 now recruiting)
Show 3 sites
  • MomDoc Women's Health Research · Scottsdale, United StatesActive, not recruiting→Completed
  • Amicis Research Center · Newhall, United StatesActive, not recruiting→Recruiting
  • Praetorian Pharmaceutical Research, LLC · Marrero, United StatesActive, not recruiting→Completed
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Amicis Research Center · Newhall, United StatesContact added t•••@amicisresearch.com · •••4708Contact added (no phone or email listed)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    3 sites changed recruiting status (2 now completed, 1 now recruiting)
    Show 3 sites
    • MomDoc Women's Health Research · Scottsdale, United StatesActive, not recruiting→Completed
    • Amicis Research Center · Newhall, United StatesActive, not recruiting→Recruiting
    • Praetorian Pharmaceutical Research, LLC · Marrero, United StatesActive, not recruiting→Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Amicis Research Center · Newhall, United StatesContact added t•••@amicisresearch.com · •••4708Contact added (no phone or email listed)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06127199
Lead sponsor
Daré Bioscience, Inc.
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 19, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Christine Mauck, MD
Contact
cmauck@darebioscience.com
www.ovaprenestudy.com
Jessica Hatheway
Contact
jhatheway@darebioscience.com
www.ovaprenestudy.com
Christine Mauck, MD
study director · Daré Bioscience, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion